Cellectis
CLLS
#9412
Rank
A$0.21 B
Marketcap
A$2.12
Share price
-1.31%
Change (1 day)
-61.86%
Change (1 year)

Earnings for Cellectis (CLLS)

Earnings in 2026 (TTM): -A$0.11 Billion

According to Cellectis's latest financial reports the company's current earnings are A$68.07 Million. In 2025 the company made an earning of -A$95.51 Million a decrease over its 2024 earnings that were of -A$51.62 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Cellectis from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -A$0.11 Billion5.47%
2025 -A$95.51 Million85.03%
2024 -A$51.62 Million-73.42%
2023 -A$0.2 Billion60.8%
2022 -A$0.13 Billion-31.26%
2021 -A$0.18 Billion27.21%
2020 -A$0.14 Billion-14.62%
2019 -A$0.17 Billion30.34%
2018 -A$0.13 Billion-15.02%
2017 -A$0.15 Billion62.18%
2016 -A$90.04 Million185.48%
2015 -A$31.54 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Regeneron Pharmaceuticals
REGN
A$7.24 B-7,727.65%๐Ÿ‡บ๐Ÿ‡ธ USA
uniQure
QURE
-A$0.29 Billion 200.62%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
-A$90.51 Million-4.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
-A$0.12 Billion 17.42%๐Ÿ‡บ๐Ÿ‡ธ USA